Please contact us for more information or to learn if you are eligible to participate.
The primary outcome measures in the phase II evaluation will be duration of symptoms, SARS-CoV-2 RNA below lower limit of quantification by nasopharyngeal (NP) swabs, and safety. The primary outcome measures in the phase III evaluation will be the composite of hospitalization due to any cause or death due to any cause, and safety.
Marissa Gomez-Martinez, MD
Luis Cantu Jr.
Type of Trial